Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 20, 2005 Stephen D. Simpson	A Healing Look at Bard Medical device maker C.R. Bard shows that boring can be beautiful so long as boring pays the bills. Investors, take note.
The Motley Fool April 21, 2006 Stephen D. Simpson	Bard Rolls On Nothing flashy here, but at the right price, this would be an interesting med-tech play. Investors, take note.
The Motley Fool July 18, 2008 Brian Orelli	St. Jude Is a Fighter The medical device maker continues to kick the competition while it's down.
The Motley Fool June 30, 2006 Stephen D. Simpson	Arrow's Erratic Flight Progress for the med-tech is still slow in coming, though market rewards have come faster. Investors, take note.
The Motley Fool April 19, 2006 Stephen D. Simpson	St. Jude Lives and Learns Though dynamics in the ICD market caught it by surprise, this is still a quality med-tech company. Investors, take note.
The Motley Fool July 21, 2010 Brian Orelli	Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now.
The Motley Fool December 3, 2010 Seth Jayson	How Boston Scientific May Be Failing You With recent TTM margins all well below historical averages, Boston Scientific has some work to do.
The Motley Fool December 7, 2010 Seth Jayson	Here's How Merit Medical Systems May Be Failing You With recent TTM operating and net margins below historical averages, Merit Medical Systems has some work to do.
The Motley Fool January 30, 2006 Stephen D. Simpson	Don't Hold Your Breath for Kensey Nash It's not over for Kensey Nash -- it will soon be seeing revenue from new partners Medtronic and Zimmer. But the stock's price continues to value this company as a growing med-tech idea.
BusinessWeek December 6, 2004 Gene G. Marcial	Boston Scientific: Anemic -- For Now Boston Scientific is far from robust -- since its summer recall of 100,000 coronary stents and since its lowered fourth-quarter profit forecast. Analysts quickly cut estimates, driving shares down from 46 in May to 33.36 on Nov. 23.
The Motley Fool April 27, 2010 Brian Orelli	Boston Scientific's "Challenging" Quarter Boston Scientific fixed its paperwork problem with the Food and Drug Administration earlier this month, but the resulting recall took its toll on first-quarter profits nonetheless.
The Motley Fool September 21, 2010 Seth Jayson	What You Need to Know About Margins at C.R. Bard Here's the current margin snapshot for C.R. Bard and some of its sector and industry peers and direct competitors.
The Motley Fool January 25, 2006 Stephen D. Simpson	Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry.
The Motley Fool January 26, 2007 Matthew Crews	Bard's Costly Quarter? The medical device company suffered from multiple one-time charges. Investors who've seen the cup as half full have fared much better here than with many other med-tech companies.
The Motley Fool March 30, 2006 Stephen D. Simpson	Arrow International's Dead Release Results at this medical device manufacturer look better than they really are. Investors, take note.
The Motley Fool May 5, 2006 Stephen D. Simpson	FoxHollow-ed Out Worries about guidance may be giving investors a second crack at this med-tech stock.
The Motley Fool July 27, 2006 Stephen D. Simpson	Growth Ingrates Dump Intuitive Surgical Despite today's sell-off, Intuitive Surgical remains a red-hot grower in the med-tech space.
The Motley Fool February 27, 2006 Stephen D. Simpson	A Foxy Idea? Medical device maker Foxhollow is in an attractive niche, but management turnover is a reason for investors to worry.
The Motley Fool May 30, 2011 Andrew Tonner	Does Varian Medical Systems Deserve a Spot in Your Portfolio? Varian looks pretty attractive with above-average return on investment, margins, and fair growth.
The Motley Fool January 22, 2009 Brian Orelli	Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Busy Day for St. Jude In addition to announcing a major acquisition, St. Jude also reported very solid financial results for the third quarter. Analysts keep raising the bar, and the medical equipment company continues to surpass it.
The Motley Fool October 31, 2005 Stephen D. Simpson	Integra Needs to Grow From Within Acquired growth is nice, but organic growth is the key to long-term success. Quite frankly, the only way this stock works from a cash flow valuation standpoint is if the company does in fact deliver very good growth over the next 10 years or so.
The Motley Fool October 19, 2005 Stephen D. Simpson	Abbott Still a Little Pale Perhaps drug and device pipelines, plus margin improvements, can put some color back into the diversified health-care company's stock.
The Motley Fool March 14, 2007 Dan Bloom	National Semiconductor's Gross Improvement Gross margins at National Semiconductor are much stronger than they were a couple of years ago. Are these shares a buy?
The Motley Fool August 10, 2010 Seth Jayson	Marginal Performance at Abbott Laboratories Keep your eye on margins.
The Motley Fool December 13, 2007 Rich Smith	Foolish Forecast: Value Line's Punchline In advance of earnings reports from Value Line, lets take a look at the company's last two quarters.
The Motley Fool February 2, 2006 Stephen D. Simpson	Cytyc Still Stands On Its Own Despite apparent doubts about some mergers, the med-tech company is still growing strongly. Investors, take note.
The Motley Fool August 23, 2006 Stephen D. Simpson	Is Medtronic Sweeping the Deck? Nothing's changing at a deep fundamental level in health care that would impede the growth of this giant med-tech corporation. However, investors need to proceed with caution.
The Motley Fool June 26, 2009 Selena Maranjian	Pursuing Profits? Meet Margins! Baffled by talk of gross, operating, or net margins? We're here to help.
The Motley Fool August 25, 2011 Jim Royal	Does CR Bard Earn Its Keep? CR Bard has not seen significant changes in its returns on invested capital over the past five years, which suggests that it is effectively maintaining its competitive position.
BusinessWeek June 7, 2004 Gene G. Marcial	St. Jude's Bruise Should Clear Up Fast St. Jude Medical (STJ ) tumbled 2%, to $73, after it revealed that the FDA had delayed for a month the approval of its new Epic CRT-defibrillator.
The Motley Fool October 19, 2005 Stephen D. Simpson	ICU, You Look Healthier An incredible third quarter shows what operating leverage can do for this little medical technology company. Investors, take note.
The Motley Fool August 4, 2006 Stephen D. Simpson	SilverHawk Flying Just Fine, Thanks With med-tech company FoxHollow Technologies, there is growth and risk in equal measure. Investors, take note.
The Motley Fool July 26, 2006 Stephen D. Simpson	Aspect Gives Investors Nightmares The med tech company continues to grow, but high volatility is likely to follow.
IndustryWeek December 1, 2004 Tonya Vinas	Succeeding Amid Savage Competition Medical-device making is one of the most competitive industries in manufacturing. For Timothy Ring, CEO of C.R. Bard Inc., beating competitors requires three key weapons.
The Motley Fool January 30, 2006 Rich Smith	Foolish Forecast: American Standard American Standard's gross margin, which wasn't impacted at all by restructuring charges, has remained strong -- even growing slightly. Investors, take note.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Stimulating Merger St. Jude will be paying $61.25 a share in cash for Advanced Neuromodulation Systems, a robust 30% premium to Friday's closing price. This deal demonstrates that large med-tech players may still be on the prowl for avenues into fast-growing new markets.
The Motley Fool October 6, 2006 Matthew Crews	Arrow International Keeps on Target Investors, with Arrow's fourth quarter and fiscal 2006 earnings in the bag, now is a good time for a checkup.
The Motley Fool September 13, 2006 Tim Beyers	Why Margins Matter What are margins? Investors, there are three that matter when studying an income statement. Let's run though each, one at a time.
The Motley Fool January 24, 2006 Rich Smith	Foolish Forecast: General Dynamics Musters Last year was good to defense contractor General Dynamics, the shares of which bucked the market's overall stagnant trend to rise as much as 20% toward year's end. Will 2006 be similarly kind?
The Motley Fool June 9, 2005 Richard Gibbons	Buying on Margins Profit margins are one useful tool for finding great stock values.
The Motley Fool April 19, 2006 Stephen D. Simpson	Abbott Gets By Will the acquisition of Guidant's vascular business kick-start this story? Abbott has shown a pretty reliable trend of getting cheap enough to buy at least once a year. Of course, the downside to that is that the stock really hasn't gone anywhere in those seven years.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool January 5, 2011 Seth Jayson	Why Wall Street Should Love C.R. Bard's Earnings With 11.4% of operating cash flow coming from questionable sources, C.R. Bard investors should take a closer look at the underlying numbers.
The Motley Fool May 4, 2006 Stephen D. Simpson	Aspect Won't Put You to Sleep High valuation of this med-tech company all but guarantees that the stock will see some volatility.
The Motley Fool March 29, 2007 Selena Maranjian	Beware Margin Borrowing High levels of margin may suggest an increase in reckless investing in the market, which might possibly lead to some kind of market meltdown.